Ventripoint Diagnostics Ltd. (VPT:CA)
Ventripoint Diagnostics Ltd. (VPT:CA)
Join the discussion | Total Conversations: 49 | Last Comment: Tue, 04 Sep 2012 - 4:15 pm EST
Get this company's news
© 2008-2013 Copyright Vantage Communications Ltd. All Rights Reserved.
VentriPoint Diagnostics – The Howard Group – Watching Closely
To view IR's commentary, please click here.........
VentriPoint Adds Three Hospitals to Clinical Trial For Congenita
To view IR's full commentary, please click here.............
VentriPoint Announces Baylor in Houston Now Enrolling Patients f
To view the full IR commentary, click here.........
VentriPoint To Present At Bloom Burton Conference
VentriPoint CEO Dr. George Adams will present at the Bloom Burton Conference this Thursday (June 21, 2012).
To view IR's commentary, More
VentriPoint Feature On “The Next Biggest Winner” Available Onlin
In case you missed it yesterday, the VentriPoint feature on the iChannel’s “The Next Biggest Winner” is now available online........
To view IR's commentary, More
VentriPoint Adds Mayo Clinic To Pulmonary Arterial Hypertension
In case you missed it, late Friday, VentriPoint announced that the Mayo Clinic is now operational in its 75 patient pulmonary hypertension study.....
To view IR's commentary, More
Multiple Hospitals Of Note Actively Enrolling Patients For Ventr
VentriPoint is on track to finalize the enrollment of 75 patients for its Pulmonary Arterial Hypertension clinical study by this summer. .......
To View IR's commentary, click here...More
VentriPoint Conquering Europe – UK, Norway, Netherlands And Now
Today, VentriPoint announced it has installed its VMS(TM) heart analysis system at the University Children’s Hospital in Zurich, Switzerland.....
To view IR's commentary, More
Another Win For VentriPoint - Health Canada Approves VMS™ 3D Tec
The 10,000 Canadians with Pulmonary Arterial Hypertension (PAH) will now have the opportunity to benefit from VentriPoint’s Medical System (VMS™)..............
To view IR's commentary, More
VentriPoint Launches Clinical Trial for Pulmonary Arterial Hyper
VentriPoint announced today that it has begun a 75 patient pivotal clinical trial to demonstrate that its VMS™ heart analysis system is equivalent to the current standard – .............
To view IR's commentary, More
VentriPoint Closes First Tranche of Financing and Ups Limit
In today’s environment, it is very hard to raise capital in the junior markets. VentriPoint believes it is not only going to achieve its initial goal to raise $2 million.............
To view IR's commentary, More
VentriPoint Gets Cash Injection from Warrants
VentriPoint received just over $680 thousand (CDN), with the exercise of a little more than 4.7 million warrants that came due between March 30 – April 4, 2012................
To view More
VentriPoint Checks Key Milestone With European CE Certification
Today VentriPoint announced that it has received CE Certification in Europe for its new VMS™ Pulmonary Arterial Hypertension application.............
To view IR's commentary, ...More
VentriPoint Lists On American OTCQX – U.S. Investors Welcome!
It was announced today that VentriPoint is now trading on the OTCQX - the premium tier of the US Over-the-Counter marketplace for non-US public companies..................
To view More
VentriPoint Is One Of Cantech’s Four Disruptive Canadian Medical
On February 24, 2012, the Canadian technology stock newsletter - Cantech Letter published an article titled “Four Disruptive Canadian Medical Device Juniors.”...........
To view IR's commentary, More
VentriPoint – Key Milestone Report - “Equivalent Accuracy To A C
It may not be readily apparent to many people yet; but a just released report on VentriPoint’s (VPT) VMS™ 3D heart measurement ...More
VentriPoint: Fund Manager Hugh Cleland Adds To Already Substanti
On February 3, 2012, Hugh Cleland, Portfolio Manager at BluMont Capital and member of VPT’s board acquired 150,000 shares in VentriPoint in the open m...More
VENTRIPOINT
Looks like Ventripoint Diagnostics is starting to make a move today , up almost 10%
VentriPoint CEO Video Update – Company Hitting All Milestones!
Recently posted to YouTube, Dr. George Adams provides investors with an update on VentriPoint. In the 2:44 minute video Dr. Adams discusses the company’s progress in 2011 and he provides an outlook for 2012.
To view IR's commentary, More
London Children’s Hospital Recognizes Advantages of VentriPoint’
Today, VentriPoint announced that it has placed the first VMS™ in a UK children’s hospital.
To view the full commentary, click here......
Wall Street Journal: Cleland Takes Hands-On Approach To Investin
In an article published today in the Wall Street Journal (WSJ), writer Ben Dummett features Blumont Northern Rivers fund manager Hugh Cleland......
To view IR's com...More
VentriPoint Listens To Customers and Launches Updated VMS™ Heart
Today, VentriPoint announced it has proactively launched what it is calling version 1.1 of its VMS™ Heart Analysis System.......
To view IR's commentary, More
Prestigious Medical Journal Publishes Article which Supports Pot
VentriPoint Diagnostics released news today that independent studies are expanding their product market capabilities.........
To view IR's commentary, click here....<...More
Christmas Starts Early for VentriPoint
Today, the company and the holders of a debenture that was due for repayment in early 2012 decided to make an exchange...............
To view IR's commentary, click here.....
EUROECHO Conference to be Presented Advantages of VentriPoint’s
VentriPoint announced today that Dr. Shelby Kutty is presenting his clinical paper on VMS™ at The Annual Congress of the European Association of Echoc...More
Leading Cardiac Institution Joins Ventripoint Clinical Trials an
VentriPoint announced today that another prestigious institution, the Children’s Hospital and Medical Center in Omaha, Nebraska has joined the clinical trials to validate its VMS™ 3D imaging technology.
To view IR's commentary, More
Video Presentations From Howard Group Opportunity Knocks III Inv
On October 24th The Howard Group hosted its 3rd annual Opportunity Knocks investor conference in Calgary..........
To view IR's commentary, click here........
Pulmonary Arterial Hypertension Validation Trials Begin
VentriPoint Diagnostics has reached a key milestone with today’s announcement that an initial Pulmonary Arterial Hypertension validation trial has started at The University of Chicago Medical Center.
To view IR's commentary, More
A Fund Manager’s Attraction To VentriPoint – An Investor & Direc
In late July we notified you of two new key board appointments to VentriPoint.....
To view the full commentary, please click here...
VentriPoint Diagnostic Appoints New CFO
Have you noticed that VentriPoint Diagnostics has been issuing an ongoing series of news releases over the past several months?..
To view IR's commentary, click here.
VentriPoint's Attributes Are Many - A Director's Perspective
He could boast of an impressive background in the healthcare and investment industry but that wouldn't be his style! ..
to view IR's commentary, click here..
VentriPoint adds Depth to its Board of Directors
VentriPoint is adding some serious talent to its Board of Directors.........
To view IR's commentary, please click her...More
VentriPoint Raises $3.5 Million
The real news here is that VentriPoint closed a $3.5 Million financing during a challenging time in the markets.
This successful milestone was achieved because:.........
To view IR's commentary, please ...More
VentriPoint Steps Into Massive Pulmonary Hypertension Market
VentriPoint announced today that they are moving forward with the validation study for pulmonary hypertension (PH) clinical development program with Dr. Robin Barst. The clinical PH expert will act as the Prin...More
VentriPoint Installs 7th VMS(TM) at Vancouver Hospital
Today VentriPoint announced its 7th installation of its VMSTM technology in St. Paul's Hospital in Vancouver. The hospital will initially use the VMSTM to monitor adult patients post congenital heart disease surgery.......
To view IR's commentary, More
Right on Track ....VentriPoint’s 5th installation
VentriPoint set a target last fall to manufacture and deploy 10 VMS 3D heart analysis units by the end of this June. In short, it is right on schedule with an additional 2 in the USA, 2 in Canada and 1 in Europe slated for installation in the coming weeks.................
To view IR's commentary, please click here..............More
VentriPoint – Advisory Board Appointment
VentriPoint keeps attracting the best and the brightest. Today’s news release is about bringing Dr. Richard Krasuski on to the Strategic Advisory board ....................
To view the full commentary, please click here..............
Ventripoint - Moving Faster Than Projected
The market needs markers to assess the potential of emerging growth stories. VentriPoint isn't only putting up sign posts, its installed lights to mark the roadway!...........
To view IR's commentary, please click here....................
Ventripoint - Moving Faster Than Projected
The market needs markers to assess the potential of emerging growth stories. VentriPoint isn't only putting up sign posts, its installed lights to mark the roadway!...........
To view IR's commentary, please click here....................
VentriPoint Attracts Pioneer In Pulmonary Hypertension
This announcement is a coup as Dr. Barst is a noted, leading cardiologist in Pulmonary Hypertension, which is abnormally high blood pressure in the arteries of the lungs, making the right side of the heart work extremely hard. Her vast experience will prove valuable with VPT planning the imminent launch of its PHT trials. Dr. Barst will be the principal investigator for the trials in the United States...............
To view IR's commentary, More
VentriPoint’s Breakthrough – Technology To Grab Centre Stage
Late last year VentriPoint raised some eyebrows with news that it was installing its heart measurement technology in a national reference hospital in Oslo, Norway.....................
To view IR's commentary, please click here..................
VentriPoint Announces First Study on Adults
Today VentriPoint announced the 4th deployment of its VMS system, and the 2nd installation in the USA. ...............
To view IR's commentary, please click here...............
FDA Approval Launches Stock
Yesterday a company called "The Medipattern Corporation" issued a news release about receiving FDA approval for one of its products. This company has Vascular Imaging software in the vein and breast space.
To view IR's commentary, please click here..............
VentriPoint Banks over $1.8 million
VentriPoint announced today that it has closed its private placement for total gross proceeds of $1,808,866. Bloom Burton & Co. Inc., of Toronto lead the raise and has acknowledged that institutions played a big part in the private placement..........
To view IR's commentary, please click here..........<...More
Advancing Research and Getting Paid To Do it....
The company recently announced its first U.S. research installation for the VMS™ 3D technology for right heart analysis. The deal was done with the University of Nebraska Medical Center/Creighton University Joint Division of Paediatric Cardiology at Children's Hospital & Medical Center in Omaha.
To view the full commentary, please click here...............More
Could a key moment be on the horizon for VentriPoint Diagnostics
The company announced today (December 8) its technology will be the subject of a key address at EUROECHO 2010, the annual European Society of Cardiology Congress, which is expected to draw over three thousand participants.....................
To view IR's commentary, please click here................
The Howard Group Introduces VentriPoint Diagnostics
Along with our detailed commentary, please note that VentriPoint made an important announcement today (Nov. 29) regarding a strategic placement of its technology in a prestigious research Hospital in Oslo, Norway.
To view IR;'s commentary, please click here...........